Non Small Cell Lung Cancer Market worth $7.9 billion by 2020
RnRMarketResearch.com adds Latest Report on Non-Small Cell Lung Cancer Market to 2020 New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market to its store.
Request a sample copy of this report at http://www.rnrmarketresearch.com/contacts/request-sample?rname=205224 .
The report focuses on the increasing differentiation between the three main NSCLC subtypes: squamous cell, adenocarcinoma, and large cell carcinoma. Common genetic and molecular aberrations within these histologies are being extensively researched and targeted by novel therapeutics and so the treatment algorithm between histological subtypes is forecast to become more differentiated over the forecast period. Most notably, patients with squamous cell carcinoma are set to benefit from crucial firstand second-line therapies in the form of Yervoy (ipilimumab) and nivolumab, having relied on generic chemotherapy for the past decade. Non-squamous patients, on the other hand, have several successful histology-specific therapies, such as Alimta (pemetrexed), and mutation-specific therapies, such as Tarceva (erlotinib), that are already marketed. New second-line entrants will create a crowded and competitive environment. The generic erosion of market leaders Alimta and Tarceva late in the forecast period will make this a tough environment for new products that have shown only minor improvements in safety or efficacy.
Despite the potential of targeted therapies and the identification of several promising molecular targets, the development of these products remains in the early-stage pipeline. Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations are likely to remain the only identified intracellular molecular aberrations targeted by marketed products, both of which are mainly found in adenocarcinoma tumors. Instead, the late-stage pipeline is primarily occupied by immunotherapies, which still offer a greater degree of specificity than chemotherapies; however, they initiate tumor destruction via the immune system. Necitumumab, Yervoy and nivolumab are all Phase III immunotherapies expected to reach the market in the forecast period, each with a different target.
Complete report is available at http://www.rnrmarketresearch.com/non-small-cell-lung-cancer-market-to-2020-new-therapies-to-enhance-treatment-segmentation-and-drive-growth-in-an-increasingly-competitive-market-market-report.html .
Resistance to targeted therapies is a significant issue in the NSCLC market as the onset of acquired resistance to therapies such as Tarceva or Xalkori (crizotinib) has greatly reduced their potential. Despite the limited late-stage pipeline activity with new molecular targets, there are new drugs targeting EGFR and ALK that may combat resistance, thereby increasing the time frame in which patients are treatable with targeted therapy. Gilotrif (afatinib) is a recently launched EGFR inhibitor with a novel mechanism of action that may delay the onset of resistance, and Zykadia (LDK378) is an ALK inhibitor in the late-stage pipeline that is set to treat Xalkori-resistant patients.
The report assesses the current NSCLC market and predicts market trends to 2020, analyzing key drivers and barriers. The areas covered include -
A disease introduction, which defines the disease and looks at symptoms, diagnosis and treatment
Analysis of the NSCLC marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, as well as the unmet needs of NSCLC treatment
Detailed analysis of the NSCLC pipeline, covering among other parameters, drug distribution by Phase, molecule type and mechanism of action. The NSCLC clinical trial landscape is analyzed with particular emphasis on failure rates across different trial Phases, as well as the trends in clinical trial size, duration and primary endpoint. This section also includes profiles and single product forecasts for the most promising pipeline drugs.
An epidemiological forecast of the major NSCLC markets, in which projected values include total and treated populations
An in-depth forecasting model for the NSCLC market, which considers the current marketed therapies in addition to the potential entry of new products to the market. The model comprises a projected outcome with high and low variance results depending on the potential performance of pipeline therapies.
Analysis of strategic consolidations within the NSCLC indication, including co-development and licensing agreements
An overview of the drivers of and barriers to the NSCLC market
RnRMarketResearch.com is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.